May 13, 2025
UnitedHealth Group CEO Andrew Witty Steps Down; Stephen Hemsley Returns as CEO
UnitedHealth Group; Andrew Witty; Stephen Hemsley; CEO transition; leadership change; personal reasons; financial guidance suspension; stock drop
Fortrea CEO Steps Down Amid Continued Stock Decline Post-Labcorp Spinout
Fortrea; Labcorp; CEO departure; stock decline; CRO spinout; leadership change; clinical trials; public company
Galapagos Reconsiders Company Split After Market Developments
Galapagos; company split; cell therapy; drug development; strategic review; leadership change; market conditions
Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug
Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases
White House Threatens Most Favored Nation Plan to Lower US Drug Prices, but Many Questions Remain
Most Favored Nation; drug pricing; White House; executive order; prescription drugs; Trump administration; US drug prices; global price comparison; pharmaceutical policy
Where AI Adds Real Value in Clinical Development: 2025 Insights
AI in clinical development; clinical trials; drug discovery; protocol design; patient recruitment; data analysis; regulatory compliance
Trump’s Drug Pricing Order Raises Questions of Effectiveness
Trump; Drug Pricing; Executive Order; Most-Favored-Nation Pricing
Roche Pledges Nearly $300M to Establish New Vabysmo Production Plant in China
Roche; Vabysmo; biopharmaceutical manufacturing; Shanghai; China; investment; eye disease treatment; plant construction; localization; green energy
Roche injects $550M into Indianapolis hub to scale up CGM production
Indianapolis, Roche (company), Continuous glucose monitoring, production, Manufacture, Investments, United States